Thermo Fisher Scientific Acquires Affinity BioReagents

Broad Range of Antibody Products Expands Thermo Fishers Protein-Research Offering

WALTHAM, Mass.--()--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has acquired Affinity BioReagents, a leading provider of antibodies, peptides, proteins and other reagents for life science research, based in Golden, Colorado.

Affinity BioReagents is an ideal complement to our existing capabilities in protein research, said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications. Such applications include Western blotting, ELISA, immunohistochemistry, flow cytometry and mass spectroscopy.

Affinity BioReagents has an offering of more than 35,000 reagents primarily monoclonal and polyclonal antibodies which are used in numerous fields of medical and academic research, as well as drug discovery. The company also provides recombinant proteins and custom antibody-production services. Affinity BioReagents had annual revenues of approximately $6 million in 2007, and will be integrated into Thermo Fishers Analytical Technologies Segment.

Antibodies are proteins generated by the immune system in response to foreign substances, binding to them and flagging them for destruction. The ability of antibodies to bind with high specificity makes them ideal research reagents for isolating and identifying molecules of interest in cells. Antibodies have become an important tool for studying protein function in disease, including such key fields as immunology, neurobiology, toxicology and cancer research.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

The following constitutes a Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the companys Quarterly Report on Form 10-Q for the quarter ended March 29, 2008, under the caption Risk Factors, which is on file with the Securities and Exchange Commission (SEC) and available in the Investors section of our Website under the heading SEC Filings. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the legacy businesses of Thermo Electron Corporation (Thermo) and Fisher Scientific International Inc. (Fisher) will not be integrated successfully; the risk that the cost savings and any other synergies from the merger of Thermo and Fisher may not be fully realized or may take longer to realize than expected; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Contacts

Thermo Fisher Scientific Inc.
Media Contact Information:
Karen Kirkwood, 781-622-1306
karen.kirkwood@thermofisher.com
Website: www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1111
ken.apicerno@thermofisher.com

Contacts

Thermo Fisher Scientific Inc.
Media Contact Information:
Karen Kirkwood, 781-622-1306
karen.kirkwood@thermofisher.com
Website: www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1111
ken.apicerno@thermofisher.com